Option chain shows key data for Korro Bio's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Korro Bio.

Korro Bio (NASDAQ:KRRO) Stock, Option Chain

KORRO BIO INC

Korro Bio

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Stock market analysts

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ALAB

ENGN

INGM

KRRO

This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Newark,,Nj,-15,Sep,2017-,Planes,From,United,Airlines,(ua)

Intraday Update

Movers

AMPS

ASPN

OKLO

United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday

Biotech

Earnings

Large Cap

Health Care

Price Target

Offerings

Small Cap

Federal Reserve

Tech

General

ASML

AVGO

IFNNF

U.S. stocks reacted positively following the Federal Open Market Committee&#39;s announcement in mid-September that it would lower interest rates by 50 basis points, wider than many analysts had anticipated.

3 Stocks That Could Rise on European Bank Interest Rate Cuts

Korro Bio Inc

Press Releases

Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

Korro to Present at the Jefferies London Healthcare Conference

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Korro to Participate in Upcoming Investor Conferences

Management

CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update

Korro to Present at the TD Cowen 45th Annual Health Care Conference

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

CAMP

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Amarin Corp

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Cargo Therapeutics

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Genfit

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

INmune Bio

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Inventiva S.A. - American Depository Shares

Inventiva

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Kodiak Sciences

Lyell Immunopharma

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nanobiotix

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

RAPT Therapeutics

Rezolute

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Tango Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

HC Wainwright & Co.

RBC Capital

Jones Trading

Raymond James

BMO Capital

Comments

Korro Bio

Korro Bio (KRRO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga